+78.8%
HBAN vs MRNA
+554.4%
-475.6%
-55.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.8% | +5.4% | -4.6% | +0.7% |
| 7D | -1.0% | -1.1% | +0.1% | -1.0% |
| 30D | -5.6% | +126.1% | -131.7% | -8.6% |
| 3M | -1.1% | +190.0% | -191.2% | -5.6% |
| 6M | +9.9% | +157.2% | -147.3% | +5.3% |
| YTD | -0.9% | +388.2% | -389.1% | -8.1% |
| 1Y | -1.4% | +467.0% | -468.4% | -9.3% |
| 3Y | +78.2% | +36.1% | +42.1% | +69.7% |
| 5Y | +37.0% | -68.0% | +105.0% | +29.0% |
| All | +78.8% | +554.4% | -475.6% | +72.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling